Examkin

Question

Difficulty: HardGynecologic Oncology

A 62-year-old female presents to the physician reporting two episodes of scant, brownish vaginal discharge over the past month. She achieved menopause at age 51. Her past medical history is notable for colon cancer treated with a right hemicolectomy at age 48, and genetic testing at that time confirmed an MLH1MLH1 gene mutation. She currently takes no daily medications. On pelvic examination, the external genitalia and vagina appear pale with loss of rugae. The cervix is flush with the vaginal vault and appears visually normal. A transvaginal ultrasound is performed in the office, revealing a homogeneous endometrial echo complex measuring 33 mm in thickness, with normal-appearing bilateral ovaries. Which of the following is the most appropriate next step in management?

  1. Endometrial tissue samplingAnswer
  2. B
    Reassurance and clinical observation
  3. C
    Topical vaginal estrogen therapy
  4. D
    Papanicolaou test with HPV co-testing
  5. E
    Diagnostic hysteroscopy with dilation and curettage

Answer

Endometrial tissue sampling
The correct answer is to perform an in-office sampling of the uterine lining. This patient has postmenopausal bleeding and a known MLH1MLH1 mutation, diagnostic of Lynch syndrome (hereditary nonpolyposis colorectal cancer). Women with Lynch syndrome have a 40% to 60% lifetime risk of developing endometrial cancer. In the general population, a transvaginal ultrasound showing an endometrial thickness of ≤4\leq 4 mm has a greater than 99% negative predictive value for endometrial cancer, and observation is appropriate. However, standard ultrasound thresholds are not adequately sensitive to rule out malignancy in patients with Lynch syndrome or those at risk for type II (non-estrogen dependent) endometrial cancers. Therefore, any postmenopausal bleeding in this high-risk population mandates immediate histologic evaluation, regardless of reassuring sonographic findings.

Step-by-Step Solution

1
Identify the patient's primary presenting symptom and medical history.
The patient has postmenopausal bleeding (brownish vaginal discharge) and a confirmed MLH1MLH1 gene mutation, indicating Lynch syndrome.
Recognizing the underlying genetic syndrome is critical for determining the appropriate diagnostic pathway, as it drastically alters cancer risk.
2
Evaluate the transvaginal ultrasound findings in the context of her specific risk profile.
The endometrial thickness is 33 mm. While a thickness of ≤4\leq 4 mm is reassuring in the general population, it is not sufficient to rule out malignancy in a patient with Lynch syndrome.
Patients with Lynch syndrome or those at risk for type II endometrial cancers can present with a thin endometrial stripe, rendering standard ultrasound cutoffs unreliable.
3
Determine the definitive next step to rule out endometrial carcinoma.
Histologic evaluation via in-office tissue sampling of the endometrium must be performed.
Tissue diagnosis is the only definitive way to rule out endometrial malignancy in patients where ultrasound cannot be reliably used for triage.

Key Concept

Patients with Lynch syndrome presenting with postmenopausal bleeding require direct histologic evaluation of the endometrium, as transvaginal ultrasound is not reliably sensitive to rule out malignancy in this high-risk population.
Estimated Time:1m 15s
Rate this question

Topics

Gynecologic Oncology

More questions from this topic